{"id":39199,"date":"2024-07-12T08:05:58","date_gmt":"2024-07-12T08:05:58","guid":{"rendered":"https:\/\/ibima.eu\/?p=39199"},"modified":"2024-10-15T10:06:28","modified_gmt":"2024-10-15T10:06:28","slug":"drnanodall","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/drnanodall\/","title":{"rendered":"DrNanoDAll"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbNanodiagnosis for Betalactam Hypersensitivity\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3″ module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

\n
\n
\n
\n
\n
\n

Financed by<\/strong>\u00a0: Instituto de Salud Carlos III \u2013 ISCIII<\/span><\/p>\n

Program<\/strong>\u00a0: EURONANOMED3-European Innovative Research & Technological Development Projects in Nanomedicine \u2013 Joint Transnational call for Proposals 2019 (JTC 2019)<\/span><\/p>\n

Project Reference:<\/b><\/span>\u00a0EURONANOMED2019-086<\/a>
<\/b><\/span><\/p>\n

Role in the project:<\/strong> Coordinator<\/span><\/p>\n

Duration:<\/span><\/b>\u00a0January 2020 to June 2024<\/span><\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
\n

Contact:\u00a0Torres Ja\u00e9n, Mar\u00eda Jos\u00e9<\/span><\/p>\n

Implementation Centre:<\/span>\u00a0<\/strong>Hospital Regional Universitario de M\u00e1laga<\/a><\/span><\/p>\n

Research group of IBIMA involved:<\/span>\u00a0Allergic Diseases to Drugs and Allergens\u00a0<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_post_title title=\u00bboff\u00bb meta=\u00bboff\u00bb image_height=\u00bb1000px\u00bb image_max_height=\u00bb124px\u00bb admin_label=\u00bbT\u00edtulo de publicaci\u00f3n\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bbArial||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#2ea3f2″ title_font_size=\u00bb35px\u00bb meta_text_align=\u00bbcenter\u00bb background_enable_color=\u00bboff\u00bb background_enable_image=\u00bboff\u00bb text_orientation=\u00bbcenter\u00bb width=\u00bb100%\u00bb max_width=\u00bb100%\u00bb module_alignment=\u00bbcenter\u00bb min_height=\u00bb100px\u00bb height=\u00bb100px\u00bb max_height=\u00bb100px\u00bb custom_margin=\u00bb27%||1%||false|false\u00bb title_font_size_last_edited=\u00bboff|desktop\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||-48px||false|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbABSTRACT\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px||19px||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

\n
\n
\n
\n
\n
\n

Betalactam (BL) allergy is self-reported by approximately 10% of the population with adverse drug reactions (ADR), being most frequently induced by an IgE mediated mechanism.\u00a0This ADR has implications for patient safety and Health Systems costs since prescription of alternative antibiotics could induce bacterial resistance, could be more expensive and could potentially be more toxic.\u00a0IgE-mediated BL allergy varies among patients, with some reacting to only one BL and others to several;\u00a0it tends to change over time and differs between European countries, depending on BL consumption.\u00a0BL allergy diagnosis is challenging, relying on patient clinical history, where previous BL-ADR evidence are often inaccurately reported, and on drug provocation and \/ or skin tests,\u00a0which are not risk-exempt and require specialized healthcare professionals for results interpretation and patient management.\u00a0In vitro testing stands out as the more rational alternative diagnostic method, showing however various limitations, such as low sensibility.\u00a0Immunoassay for quantifying specific IgE is the most used, although limited to few BLs.\u00a0<\/span><\/p>\n

Basophil activation test is also used, although the lack of knowledge about the activation mechanisms has hampered a wider clinical application.\u00a0<\/span>Thus, nowadays these tests do not fulfill the clinician\u2019s needs.\u00a0DrNanoDAll proposes the development of nanoparticles decorated with BL dendrimeric antigens, innovative solutions to surpass the current limitations.\u00a0In order to offer new in vitro tools for BL-allergy accurate diagnosis,\u00a0this proposal will combine nanotechnological and immunological approaches with BL-allergy clinical expertise, implementing a multi-omics workflow and involving the industry for scaling up nanomaterials and clinical test validation steps.\u00a0<\/span><\/p>\n

This European-wide collaboration will be crucial to generate a new BL-allergy diagnosis tool suitable for personalized medicine, which will impact positively on the European Health Systems.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

\n
\n
\n
\n
\n
\n

Website of the Project<\/a><\/span><\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][et_pb_heading title=\u00bbPartners\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ custom_margin=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n